5 ALPHA REDUCTASE GENOTYPE, RACE PROSTATE CANCER RISK

描述：(改编自《调查人员摘要》)前列腺癌 目前在美国男性中最常见的癌症。前列腺癌的调节 细胞生长在很大程度上受雄激素的控制，尤其是 双氢睾酮(DHT)。这种化合物是由雄性激素合成的。 前列腺癌中编码的5-α还原酶分泌的睾酮 由SRD5A2基因决定。前列腺癌的病因似乎包括 类固醇5-α还原酶活性增加，特别是在种族/民族之间 前列腺癌风险差异很大的人群，如高危人群 非洲裔美国人和风险较低的亚洲人是风险的两个极端群体。我们 已经确定并表征了SRD5A2基因的遗传变异性 美国的不同种族/民族以及前列腺癌病例和 控制。这些调查利用了洛杉矶的一个大型多民族队列。 洛杉矶和夏威夷。我们建议在SRD5A2研究的基础上再接再厉 基因和前列腺癌的流行病学、遗传学和生物化学方法。它 我们的总体假设是SRD5A2基因座的遗传变异对 在前列腺癌的易感性和进展中的重要作用 解释风险的种族/民族差异。为此，我们打算 调查以下相互关联的六个具体目标：1)确定所有 整个SRD5A2基因的构成(生殖系)DNA变异 可能导致前列腺癌的易感性；2)确定 特异靶基因1中确定的各变异体与前列腺的关系 种族/民族人群的癌症风险：4)识别体细胞突变 在参与前列腺癌进展的SRD5A2基因中；5)特征 鉴定出的体细胞DNA遗传变异体的生化特性 体外模型系统中的特异性靶点1和4；6)确定 SRD5A2基因体细胞DNA遗传变异对前列腺癌的影响 癌症在种族/民族群体内部和之间发展。因此，我们将 前列腺癌及其易感性的分子基础研究 以分子流行病学为基础的多学科研究进展 高危患者症状前识别的重要意义 有针对性的化学预防和改进这种疾病的治疗。

DESCRIPTION: (Adapted from the Investigator's Abstract) Prostate cancer is currently the most common cancer among American men. Regulation of prostatic cell growth is largely controlled by androgens including especially dihydrotestosterone (DHT). This compound is synthesized from the male hormone testosterone by the enzyme 5-alpha reductase which is encoded in the prostate by the SRD5A2 gene. The etiology of prostate cancer appears to include increased steroid 5-alpha reductase activity particularly across racial/ethnic groups which are at very different risk for prostate cancer, such as high-risk African-Americans and lower risk Asians, the two extreme groups for risk. We have identified and characterized genetic variability in the SRD5A2 gene among various racial/ethnic groups in the US and between prostate cancer cases and controls. These investigations made use of a large multiethnic cohort in Los Angeles and Hawaii. We propose to build on and expand our studies of the SRD5A2 gene and prostate cancer by epidemiologic, genetic and biochemical methods. It is our overall hypothesis that genetic variation at the SRD5A2 locus plays a significant role in predisposition to and progression of prostate cancer and in explaining the racial/ethnic variation of risk. To this end, we intend to investigate the following interrelated six specific aims: 1) To identify all constitutional ("germline") DNA variations across the entire SRD5A2 gene that might contribute to predisposition to prostate cancer; 2) To determine the relationship between each variant identified in Specific Aim 1 to prostate cancer risk in for racial/ethnic populations: 4) To identify somatic mutations in the SRD5A2 gene involved in prostate cancer progression; 5) To characterize the biochemical properties of the somatic DNA genetic variants identified in Specific aims 1 and 4 in an in vitro model system; 6) To determine the contribution of somatic DNA genetic variants in the SRD5A2 gene to prostate cancer progression within and across racial/ethnic groups. Therefore, we will investigate the molecular basis of predisposition to prostate cancer and its progression in a multidisciplinary study rooted in molecular epidemiology with significant implications for presymptomatic identification of at-risk individuals, targeted chemoprevention and improved treatment of this disease.